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Abstract
 
Antibody diversity creates an immunoregulatory challenge for T cells that must cooperate with
B cells, yet discriminate between self and nonself. To examine the consequences of T cell reac-
tions to the B cell receptor (BCR), we generated a transgenic (Tg) line of mice expressing a T
cell receptor (TCR) specific for a 
 
 
 
 variable region peptide in monoclonal antibody (mAb) 36-71.
The 
 
  
 
epitope was originally generated by a pair of somatic mutations that arose naturally during
an immune response. By crossing this TCR Tg mouse with mice expressing the 
 
  
 
chain of
mAb 36-71, we found that 
 
 
 
-specific T cells were centrally deleted in thymi of progeny that
inherited the 
 
 
 
Tg. Maternally derived 
 
 
 
Tg antibody also induced central deletion. In marked
contrast, adoptive transfer of TCR Tg T cells into 
 
 
 
Tg recipients resulted in T and B cell acti-
vation, lymphadenopathy, splenomegaly, and the production of IgG antichromatin antibodies
by day 14. In most recipients, autoantibody levels increased with time, Tg T cells persisted for
months, and a state of lupus nephritis developed. Despite this, Tg T cells appeared to be tolerant
as assessed by severely diminished proliferative responses to the V
 
 
 
 peptide. These results reveal
the importance of attaining central and peripheral T cell tolerance to BCR V regions. They
suggest that nondeletional forms of T tolerance in BCR-reactive T cells may be insufficient to
preclude helper activity for chromatin-reactive B cells.
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Introduction
 
The sequence diversity within Ab V regions presents a
challenge to a CD4
 
 
 
 T cell repertoire that provides help to
B cells during humoral immunity, yet seems to avoid help-
ing B cells with self-reactive receptors under physiological
circumstances. Although several studies have provided evi-
dence that the T cell repertoire attains a state of tolerance
to germline-encoded Ab sequences (1, 2), it is unknown
whether tolerance results from T cell interactions with self-
presenting B cells or with soluble Ab products presented by
professional APCs and whether tolerance occurs primarily
in the thymus or the periphery. Moreover, almost nothing
is known regarding T cell tolerance to somatically gener-
ated V region sequences.
Various experimental models have revealed that failure
to develop or maintain tolerance to Ig-derived peptides
results in either B cell death, or survival of B cells that no
longer present antigenic T cell epitopes (e.g., through
isotype switching; references 3–7). However, in models
where tolerance is not attained, T cells specific for self-
antigens that are ubiquitously expressed by B cells can in-
duce B cell activation and autoantibody production (8–11).
Given that B cells can self-present clonally unique B cell
receptor (BCR)–derived peptides (1, 12–16), we and
others have proposed that such peptides might provide an
unregulated avenue of help for B cells in spontaneous
systemic autoimmunity. Several studies in spontaneously
lupus-prone mice have provided support for this idea
(17–23).
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To investigate the consequences of a T cell encounter
with a BCR-derived peptide, we generated a complemen-
tary pair of transgenic (Tg) mice. Our 
 
 
 
Tg mice express
the 
 
  
 
chain of mAb 36-71, in which a class II–restricted T
cell epitope is located within V
 
 
 
 framework-1 (FR1). This
epitope was originally created by two somatic mutations in
codons 7 and 8 (1, 2). CA30 Tg mice express correspond-
ing 
 
  
 
 TCR transgenes encoding a receptor specific for
the V
 
 
 
 36-71 epitope. We found that central tolerance was
tight in double Tg mice. However, adoptive transfer of
mature CA30 T cells into 
 
 
 
Tg recipients resulted in multi-
clonal B cell activation, antinuclear antibody production,
and lupus nephritis. This was associated with a persistence
of CA30 T cells that, paradoxically, appeared to be refrac-
tive in proliferation assays. Although our results underscore
the importance of maintaining specific T cell tolerance to
Ig V regions, they suggest that nondeletional forms of tol-
erance may be insufficient to protect against the develop-
ment of antinuclear Ab.
 
Materials and Methods
 
Tg Mice.
 
 
 
Tg and Ars/A1 mice were described previously
(1, 24). The 
 
 
 
Tg and 
 
  
 
 Tg mice were crossed to an A/J genetic
background (8 and 10 backcrosses, respectively). To produce
CA30 Tg mice, 
 
 
 
 and 
 
 
 
 TCR genes of the hybridoma A30.2.11
were amplified by PCR from cDNA using DyNAzyme (Finn-
zyme Oy; MJ Research Inc.) and primers 1 and 2 (
 
 
 
) or 3 and 4
(
 
 
 
). All primers are listed in Table S1 (available at http://www.
jem.org/cgi/content/full/jem.20031234/DC1). The resulting PCR
products were cloned independently into the EcoRI site of the
VA-CD2 vector, provided by D. Kioussis (Medical Research
Council, London, England, UK; references 25–27). The V gene
sequences were verified, using the sequencing primers 5–8. TCR
V
 
 
 
1 and V
 
 
 
8.2 sequences were identical to those published (Na-
tional Center for Biotechnology Information accession no. XM
290046; reference 28). CDR3 sequences are listed in Fig. S1 A.
After removal of plasmid sequences, the TCR 
 
 
 
–
 
 
 
and
 
  
 
–contain-
ing constructs were mixed together in equal proportions, and Tg
mice were produced using standard techniques.
s
 
MHC Tetramer Construction.
 
Using an overlapping primer
strategy, an oligonucleotide encoding the V
 
 
 
 36-71 FR1 peptide
(DIQMTQIPSSLSA) was linked to the 5
 
 
 
 end of the gene en-
coding the 
 
 
 
 chain of I-A
 
k
 
. To this end, the vector pBACp10ph
(provided by J. Kappler, National Jewish Medical and Research
Center, Denver, CO; reference 29), containing an I-A
 
k
 
 con-
struct, was used in two rounds of PCR as a template for primers
11 and 12, and 11 and 13. Primers 12 and 13 contained DNA en-
coding the V
 
 
 
 36-71 peptide sequence. The resulting DNA con-
sisting of the 5
 
 
 
 end of the I-A
 
k
 
 
 
 
 
 construct connected to DNA
encoding the V
 
 
 
 36-71 peptide was cloned into pBACp10ph
(29) using the EcoRI and SpeI sites, and the integrity of the con-
struct was verified by sequencing.
To increase protein stability, a leucine zipper was introduced
to the carboxy terminal ends of the 
 
 
 
 and 
 
 
 
 chains. A plasmid
encoding the zipper templates was provided by J. Bill (University
of Colorado School of Medicine, Denver, CO). The basic zipper
chain was linked to an I-A
 
k
 
 
 
 
 
 chain, and the acidic zipper chain
was linked to the I-A
 
k
 
 
 
 
 
 chain. The acidic zipper template was
amplified with primers 14 and 15 and cloned into the I-A
 
k
 
 
 
 
 
gene using the NheI and SphI restriction sites. The basic zipper
template was amplified with primers 17 and 18, introduced into
the I-A
 
k
 
 
 
 
 
 gene via amplification with primers 16 and 17 and
cloned into the pBACp10ph vector (29) using XhoI and KpnI
sites. This strategy destroyed the thrombin cleavage sites. Se-
quence verification revealed zipper sequences that were other-
wise identical to those published previously (30).
Soluble I-A
 
k
 
-peptide tetramers were produced as described
previously (29, 31, 32). Soluble I-A
 
k
 
 protein was detected with
mAb 10.3.6 (33) and biotinylated mAb 11.5.2 (33) and affinity
purified with sepharose conjugate of anti–I-A
 
k
 
 mAb 10.3.6.
Bound protein was washed in sodium bicarbonate (50 mM, pH
8) and eluted with sodium carbonate (50 mM, pH 11). Staining
with the tetrameric reagent was performed at 37
 
 
 
C for 3 h before
the addition of secondary antibodies for FACS
 
®
 
 analysis.
 
Cell Purification.
 
Single cell suspensions were obtained from
thymi, LNs, or spleens as described previously (1). Thymocytes and
LN cells were used without further manipulation unless otherwise
indicated. Erythrocytes were removed from splenocyte prepara-
tions by lysis with ammonium chloride. In some cases, splenocyte
APCs were fractionated on the basis of their specific gravity with
Percoll as described previously (1). For most proliferation assays
and intracellular cytokine detection, T cells were isolated by nega-
tive selection following the StemSep™ magnetic separation proto-
col (StemCell Technologies Inc.). Typically, this protocol yielded
T cells that were 85–95% pure as judged by FACS
 
®
 
 analysis.
 
Adoptive Transfers, Immunizations, and Injections.
 
CA30 LN
cells were isolated as aforementioned, washed once in PBS, and
injected into a lateral tail vein of A/J or 
 
 
 
Tg recipient mice (not
irradiated). Some recipient mice were immunized with 30 
 
 
 
g of
V
 
 
 
 36-71 peptide emulsified in CFA and injected either intra-
peritoneally or subcutaneously. Spleens or draining LNs were
harvested for proliferation and cytokine assays.
 
Flow Cytometry.
 
Conjugated mAbs were purchased from BD
Biosciences, and cells were stained using standard staining proce-
dures. Biotinylated antibodies were visualized with streptavidin-
PE (Biosource International) in most cases. Cells were analyzed
on FACsCalibur™ or FACscan™ flow cytometers using CELL
Quest™ software (Becton Dickinson).
 
Proliferation Assays.
 
Various numbers of purified T cells were
cultured with a fixed number (2 
 
 
 
 10
 
5
 
) of lightly irradiated (1,100
rad) splenocytes as a source of APCs from an unmanipulated
mouse. Stimulator peptide was added at the indicated concentra-
tions, and the culture was incubated for 4–5 d at 37
 
 
 
C in 5% CO
 
2
 
.
[
 
3
 
H]Thymidine (1 
 
 
 
Ci/well) was added during the final 20 h of
culture, and incorporation was detected with a Wallac Microbeta,
using Beta-Scint scintillation fluid (both obtained from Wallac).
 
Analysis of Serum Antibody.
 
Chromatin-specific serum IgG
was detected on plates coated with either 10 
 
 
 
g/ml of mouse
chromatin or 10 
 
 
 
g/ml BSA. Total IgG was detected on plates
coated with 5 
 
 
 
g/ml Fc-specific goat anti–mouse IgG (Sigma-
Aldrich). All assay plates (Corning) were coated overnight at 4
 
 
 
C
and incubated with blocking buffer (2% BSA, 1% gelatin in PBS
containing 0.05% Tween 20) for 1–2 h at 37
 
 
 
C or room temper-
ature (RT). Mouse serum was incubated at the indicated dilu-
tions for 1 h at 37
 
 
 
C or RT. IgG antibodies were detected with
biotinylated goat anti–mouse IgG (Southern Biotechnology As-
sociates, Inc.) followed by europium-labeled streptavidin (Wal-
lac). Europium fluorescence at 615 nm was measured as described
previously (1). Chromatin-specific Ig isotypes were detected with
horseradish peroxidase–coupled goat anti–mouse isotype-specific
antibodies (Southern Biotechnology Associates, Inc.) followed by
colorimetric detection of 2,2
 
 
 
-azino-bis(3ethylbenz-thiazoline-6-
sulfonic acid) at 405 nm (Victor 2; Wallac). 
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Analysis of Antinuclear Antibodies.
 
Sera from individual mice
were incubated for 30 min in a humidified chamber on slides
containing NOVA-Lite HEP-2 cells (Inova Diagnostics). Anti-
nuclear antibodies were detected with a FITC-labeled F(ab)
 
2
 
fragment of goat anti–mouse IgG (Fc specific; Sigma-Aldrich).
 
Analysis of Kidney Pathology.
 
For tests of Ig deposition, kid-
neys were quick frozen in Tissue-Tek OCT (Sakura Finetek Eu-
rope B.V.) and stored at 
 
 
 
80
 
 
 
C. Serial sections of 6–8 
 
 
 
m were
transferred to positively charged microscope slides (ProbeonPlus;
Fisher Scientific), fixed in acetone, and stored at 
 
 
 
80
 
 
 
C. Sections
were thawed at RT and blocked with 5% FCS in PBS for 10 min
at RT. Subsequently, the sections were incubated with FITC-
coupled goat anti–mouse isotype antibodies for 30 min at RT.
Sections were mounted using Gel/Mount (Biomeda). Images
were taken on a Marianas workstation using Slidebook 4.0.6.4
(both obtained from Intelligent Imaging Innovations, Inc.). He-
matoxylin and eosin (H&E) staining was performed on kidneys
fixed in 1% formalin by the Histology Core Laboratory at the
National Jewish Medical and Research Center.
 
Online Supplemental Material.
 
Table S1 lists the primers used
in the project. Table S2 gives weights and numbers of cells in
LNs and spleens of 
 
 
 
Tg recipients on day 10. Table S3 illustrates
activation markers on B cells at day 10 in 
 
 
 
Tg mice that received
different numbers of CA30 cells. Table S4 shows the Ig isotypes
of antichromatin antibodies. Fig. S1 illustrates normal expression
levels and allelic exclusion of the CA30 transgene-encoded
TCR. Fig. S2 shows intracellular IL-2 in stimulated CA30 cells.
Fig. S3 illustrates poor allelic exclusion in peripheral CD4 cells of
double Tg mice. Fig. S4 shows the total IgG and antichromatin
titers in sera of recipients of 10
 
7
 
 CA30 cells. Kidney pathology in
recipients of CA30 cells is compared at days 28 and 130 in Fig.
S5. Online supplemental material is available at http://www.jem.
org/cgi/content/full/jem.20031234/DC1.
 
Results
 
Phenotype of CA30 Tg T Cells.
 
To study CD4 T cell
reactions to antibody V region diversity, we developed two
complementary lines of Tg mice. One line expresses the 
 
 
 
chain of mAb 36-71, which contains a well-characterized
T cell epitope, created by a pair of somatic mutations at
codons 7 and 8 within FR1 (1, 2). Expression of endoge-
nous Ig heavy chains in these mice creates a relatively di-
verse B cell repertoire with normal numbers of resting B
cells (1). The second line of Tg mice (CA30) expresses an
 
  
 
 TCR from hybridoma A30.2.11, which is specific for
the V
 
 
 
 36-71 peptide presented in the context of I-A
 
k
 
. In
CA30 Tg mice, 
 
 
 
90% of CD3
 
 
 
 LN cells were CD4
 
 
 
 and
V
 
 
 
8
 
 
 
, and the level CD3 expression was nearly identical
among CD4
 
 
 
 T cells of Tg and nonTg littermates (Fig. 1 A
and see Fig. 2 D, and Fig. S1 B, available at http://
www.jem.org/cgi/content/full/jem.20031234/DC1).
To identify Tg T cells, we also developed a covalent V
 
 
 
36-71–I-A
 
k
 
 tetrameric staining reagent. The tetramer stained
V
 
 
 
 36-71–specific T cell hybridomas and 
 
 
 
95% of periph-
eral CD4 T cells in CA30 Tg mice (Fig. 1 A and see Fig. 2
D). Allelic exclusion appears to be tight in Tg mice, as 
 
 
 
1%
of the peripheral CD4 T cells expressed an alternative en-
dogenous 
 
 
 
 chain (V
 
 
 
2) in both young and adult mice (Fig.
1 B and Fig. S1 C). In addition, CD44 expression was re-
duced in frequency among T cells of naive CA30 Tg mice
relative to nonTg littermates, indicating that few T cells had
encountered cognate Ag in CA30 mice (unpublished data).
Specificity and Function of CA30 Tg T Cells. To assess
the biological activity of CA30 T cells, we performed a se-
ries of in vitro and in vivo tests. Initially, LN cells were la-
beled with carboxyfluorescein diacetate succinimidyl ester
(CFSE) and stimulated with various concentrations of V 
36-71 peptide. 2 d later, the cultures were analyzed by
FACS® for tetramer staining and CFSE fluorescence. At
high peptide concentrations, virtually all of the tetramer 
cells had undergone at least one round, and most cells had
undergone two rounds of division (Fig. 1 C). Furthermore,
nearly all of these cells produced IL-2 as measured by intra-
cellular cytokine staining (Fig. S2, available at http://
www.jem.org/cgi/content/full/jem.20031234/DC1).
CA30 T cells were also directly stimulated by  Tg sple-
nocytes. As predicted from our previous studies (1) and
shown in Fig. 1 D, CA30 Tg T cells proliferated vigorously
to low density splenocytes (    1.079) from  Tg mice.
Similarly, CA30 T cells were strongly stimulated by spleno-
Figure 1. Tg expression and
allelic exclusion in CA30 TCR
Tg mice. (A) Comparison of
CD3 levels and tetramer staining
(V  36-71 FR1-I-Ak) in CD4 
LN cells from CA30 (dark line)
and nonTg (shaded histogram)
mice. (B) Allelic exclusion in
CD4 , CA30 cells. V 2 is the
only A/J   V region for which a
specific antibody is available.
(C) Proliferation of tetramer 
cells in vitro as assessed by loss of
CFSE intensity after 2 d in culture
with indicated concentrations of
V  36-71 peptide. (D) Proliferation of CA30 T cells as assessed by [3H]thymidine incorporation after 2 d in culture with various numbers of splenocytes
from anergic Ars/A1 mice (closed triangles) or  Tg mice (closed circles, high density,    1.079; open squares, low density,     1.079). The number of
B cells per well was calculated based on the frequency B220 positive cells. (E) In vivo stimulation of CA30 T cells. LNs were harvested from nonTg A/J
mice that received 2   106 CA30 Tg LN cells and were either immunized subcutaneously (closed symbols) or not (open symbols) with 30  g of V  36-71
peptide in CFA. T cells were purified and proliferation was measured by [3H]thymidine incorporation.T Cell Reactions to a   Variable Region Sequence 4
cytes containing anergic Ars/A1 Tg B cells, which express
the mAb 36-71   chain in conjunction with a    Tg (24).
In contrast, proliferation induced by high density resting
splenocytes was weak in agreement with our previous find-
ings (1). For in vivo tests of biological activity, 2   106
CA30 Tg LN cells were transferred into nonTg recipients.
Immediately after transfer, the recipient mice were immu-
nized subcutaneously with the V  36-71 peptide emulsi-
fied in CFA. T cells recovered from peripheral LNs of re-
cipient mice at day 10 responded strongly to the V  36-71
peptide in vitro, both by proliferation and intracellular IL-2
production (Fig. 1 E and not depicted).
Thymic Deletion of CA30 T Cells in Mice Expressing V 
36-71. In a test for central tolerance, CA30 Tg mice
were bred to Tg mice expressing the   chain of mAb 36-
71. Fig. 2 A shows representative FACS® analyses of thy-
mic and LN cells from double Tg mice and age-matched
controls. Compiled data from several mice are shown in
Fig. 2 (B and C). In addition to the percent decrease in
CD4 cells shown in Fig. 2 (A–C), a total reduction of 30–
40-fold in CD4  cell numbers was seen in thymi and LNs
of double Tg mice (not depicted). This large reduction in
cell numbers is consistent with central thymic deletion at
the CD4 /CD8  double-positive stage.
A closer analysis of peripheral CD4 T cells in double Tg
mice indicated that very few of these cells expressed the Tg
receptor, as shown by MHC tetramer staining (Fig. 2 D).
Relative to CA30 Tg mice, double Tg mice had a higher
percentage cells expressing V 2 among CD4  T cells (Fig.
S3, available at http://www.jem.org/cgi/content/full/jem.
20031234/DC1), although this percentage was similar to
that in age-matched nonTg littermates. These appear to be
cells that escaped thymic deletion due to incomplete en-
forcement of allelic exclusion by the TCR Tg mice. Con-
sistent with the low proportion of tetramer staining cells in
double Tg mice, purified LN T cells from such mice failed
to proliferate above background levels to the V  36-71
peptide (Fig. 2 E). This result further reveals the extent of
CD4  T cell tolerance to the V  epitope.
Central Tolerance Induced by Maternally Derived V  36-
71. To test whether APCs that process and present exog-
enous antibody could mediate thymocyte deletion, we ana-
lyzed offspring of  Tg mothers that had inherited the TCR
Tg but not the   transgene. These mice should only be ex-
posed to maternally derived   Ig transmitted either trans-
placentally or through milk. In very young mice (2–3.5 wk
of age), we observed profound deletion of Tg T cells in
both the thymus and the periphery (Fig. 2, F and G).
However, the CD4 T cell populations began recovering
shortly after weaning, and by 7 wk of age, the percentages
of CD4, V 8, and tetramer-staining populations were
nearly normal (Fig. 2 G and not depicted). Moreover,
Figure 2. Central deletion of
CA30 CD4  T cells in mice that
produce the  Tg Ab or that have
maternally derived  Tg Ab. (A)
Representative FACS® plots of
thymic and LN cells from double
Tg, CA30 single Tg (derived
from TCR-only breeders), and
 Tg adult mice stained with
anti-CD4 and CD8. (B and C)
Frequencies of single positive
CD4  thymic and LN T cells
from multiple mice represented
graphically. (D) Percentages of
CD4 T cells among total LN
cells and of V  36-71–I-Ak
tetramer  cells among CD4 T
cells. (E) Proliferation of LN T
cells purified and stimulated with
1  M V  36-71 peptide for 5 d.
(F) Representative FACS® plots
of thymocytes from 2.5-wk-old
offspring of a male CA30 mouse
bred with a female  Tg mouse.
(G) Frequencies of CD4  cells
among CD4  LN cells from
CA30 single Tg progeny of  Tg
mothers.Snyder et al. 5
V 2-expressing T cells were more abundant in young than
adult CA30 Tg offspring of  Tg mothers (unpublished
data). These results demonstrate that V -specific T cells are
subject to deletion by maternally derived antibody, and that
the repertoire recovers with time presumably due to anti-
body clearance.
T Cell Activation in  Tg Adoptive Recipients of CA30
Cells. Although our results implicated central tolerance as
a mechanism to regulate Ig V region–specific CD4 T cells,
they did not address possible redundant regulation by pe-
ripheral tolerance mechanisms. To test for peripheral toler-
ance, we transferred 107 CA30 LN cells into  Tg recipients
or control A/J recipients. By 3 d after transfer, the Tg T
cells had expanded dramatically in  Tg recipients, as as-
sessed by tetramer staining and loss of CFSE fluorescence in
cells that were labeled before transfer. At day 10, tetramer-
binding T cells uniformly expressed elevated levels of
CD44 and still comprised a large percentage of splenic and
LN T cells (Fig. 3 A). Furthermore,  Tg recipients of
CA30 LN cells that were killed 10 d after transfer displayed
enlarged LNs and spleens, suggesting massive proliferation
(Fig. 3 B, left, and Table S2, available at http://www.jem.
org/cgi/content/full/jem.20031234/DC1). Even 28 d af-
ter transfer, the spleens of  Tg mice receiving 107 CA30
cells were still dramatically enlarged, and tetramer-binding
T cells comprised  30% of the splenic CD4 T cell popu-
lation (Fig. 3 C). Although splenic architecture was gener-
ally intact, the white pulp was significantly expanded, par-
ticularly follicles and germinal centers. Similar but less
dramatic results were obtained upon transfer of fewer
CA30 cells into  Tg recipients (Fig. 3 B, right). Transfer
of 106 CA30 cells induced less severe lymphadenopathy
and splenomegaly at day 10, in which 7–11% of LN and
splenic CD4  cells were tetramer . 105 CA30 T cells in-
duced lymphadenopathy without splenomegaly, in which
tetramer staining cells comprised  3% of the peripheral
CD4  population.
T Cells Become Refractive with Time after Transfer. T cells
were recovered from  Tg recipients and tested for prolifer-
ative responses to the V  36-71 peptide in vitro. Interest-
ingly, T cells recovered 10 d after transfer responded
strongly, whereas those recovered 28 d after transfer did
not proliferate above background levels (Fig. 3 D). More-
over, immunization with V  36-71 peptide emulsified in
CFA did not restore the proliferative capacity of the T cells
recovered at day 28 (Fig. 3 D). As assayed by proliferation,
Figure 3. Activation and proliferation of B and T
cells in  Tg recipients of CA30 cells. (A) Representa-
tive FACS® plots of tetramer  T cells at 3 and 10 d after
injection of 107 CA30 LN cells into  Tg recipients
(dark line) or control A/J recipients (shaded histo-
gram). Day 3 tetramer staining is shown for CD4-gated
cells, and day 10 tetramer staining is shown for CD4 ,
CD16/CD32  cells. CFSE profile is shown for
tetramer , CD4  cells. CD44 profile is shown for
tetramer-gated cells (dark line) and tetramer  cells
(shaded histogram). (B) LNs and spleens harvested from
mice 10 d after CA30 cell transfer. Spleen images are
not proportional to lymph node images (left). (C) Rep-
resentative FACS® plots of tetramer  T cells 28 d after
the injection of 107 CA30 LN cells into a  Tg recipient.
Tetramer staining is shown for CD4 , CD16/CD32 
splenocytes. CD44 staining and forward scatter (FSC)
analyses are shown for tetramer  cells (dark lines) and
tetramer  T cells (shaded histograms) from the same
mouse. (D) Proliferation of purified T cells from
spleens or LNs of  Tg recipients 10 d (closed circles)
after transfer or from spleens of  Tg recipients (open
triangles) and A/J recipients (closed triangles) 28 d after
transfer. The purified T cells were stimulated for 5 d
with 1  M of V  36-71 peptide. Immunized  Tg
recipients (closed squares) were injected i.p. on day 24
and isolated on day 28 for proliferation tests.T Cell Reactions to a   Variable Region Sequence 6
these results indicate that the transferred T cells were func-
tional early, but rendered tolerant with time.
B Cell Activation in  Tg Adoptive Recipients of CA30
Cells. We also investigated the effect of transferred CA30
T cells on B cells. As shown in Fig. 4 A,  Tg B cells in re-
cipients of 107 CA30 cells expressed increased levels of acti-
vation markers. On day 3 after transfer, CD86 levels were
increased on most B cells in LNs and spleen, whereas high
levels of CD69 were expressed on most B cells in LNs and
 35% of B cells in the spleen. By day 10, CD86 expression
remained high on a substantial fraction of splenic B cells,
whereas CD69 was elevated on  50% of splenic B cells. In
contrast, B cells of A/J mice that received CA30 cells had
staining profiles identical to those of control uninjected  Tg
mice (unpublished data). Qualitatively similar results were
seen in  Tg mice that received fewer CA30 cells. However,
in these recipients, frequencies of B cells expressing CD86
and CD69 were reduced relative to those of mice that re-
ceived 107 CA30 cells (Table S3, available at http://www.
jem.org/cgi/content/full/jem.20031234/DC1).
We quantified serum Ig levels in several of the  Tg re-
cipients and observed significant increases in total IgG lev-
els by day 14, with further increases at day 28 (Fig. 4, B and
C). By day 76, IgG titers were still high, although reduced
somewhat relative to those of day 28, and further reduc-
tions were evident at day 126, when titers approached
baseline levels seen in control A/J recipients (Fig. 4, D and
E). The same trend was observed in a second experiment
involving five  Tg recipients (Fig. S4, available at http://
www.jem.org/cgi/content/full/jem.20031234/DC1). This
observation suggests that the  Tg recipients of CA30 cells
were able to recover from a multiclonal B cell response that
occurred at early time points.
Development of Antichromatin Ab in  Tg Adoptive Recipients
of CA30 Cells. Significant titers of antichromatin IgG an-
tibodies were observed in sera of all  Tg recipients tested at
days 14 and 28 after adoptive transfer (n   9; Fig. 5, A and
B, and Fig. S4 B). The presence of antinuclear antibodies
was verified by staining of HEP-2 cells (Fig. 5, C and F).
However, only a small fraction of total serum IgG bound
chromatin at these early time points. On day 14, the con-
centration of antichromatin IgG in  Tg recipients was
 1–2  g/ml, whereas total IgG concentration was several
milligrams per milliliter. Moreover, from days 14 to 28,
chromatin-specific IgG increased only proportionally to the
total increase in IgG. These data indicate that the transferred
T CA30 cells initially activated not only chromatin-specific
B cells but also B cells with other antigenic specificities.
However, with time, chromatin-specific antibodies in-
creased in both absolute and relative terms, with some vari-
ability among individual mice. In an initial experiment,
titers of anti-chromatin antibodies were substantially in-
creased in two out of four  Tg recipients at day 76 relative
to titers measured on day 28. One of these mice main-
tained elevated levels through day 126 (Fig. 5 E). In a sec-
ond experiment, five out of five recipients demonstrated
elevated antichromatin titers that were retained for at least
4 mo after transfer (Fig. S4 B). Using the high-affinity
3H9/V 4 as a quantitative standard (34, 35), we deter-
mined that the concentrations of antichromatin Ab ranged
from 7–70  g/ml at day 130. Collectively, the serological
analyses indicated that, in most  Tg recipients, chromatin-
specific B cells were preferentially stimulated to produce
Ab as time progressed after CA30 cell transfer.
Persistent CA30 T Cells in Most  Tg Recipients. We
speculated that failed tolerance in CA30 T cells might ac-
count for a prolonged production of autoantibodies in most
of the recipients. To test this idea, we first assayed for tet-
ramer-binding cells in blood samples from the four  Tg re-
cipients of the initial experiment. Tetramer  cells were
only observed in the two recipients (nos. 3 and 4) that con-
tained high titers of antichromatin Ab at day 76 (unpub-
lished data). In a more rigorous test for Tg T cells, we im-
munized the two mice with lower autoantibody levels
Figure 4. Activation of  Tg B cells and induction of IgG antibody in
 Tg recipients of CA30 cells. (A) Representative FACS® plots showing
forward scatter (FSC), CD69, and CD86 for B220-gated cells at 3 and 10
d after CA30 cell transfer. (B–E) IgG antibody detected in sera of  Tg
(open symbols) and A/J (closed symbols) recipients at the indicated days
after CA30 cell transfer. Binding assays for all sera were conducted on the
same day.Snyder et al. 7
(nos. 1 and 2) and stained splenocytes 3 d later (day 126) for
tetramer-binding cells. Despite immunization, the frequen-
cies of tetramer  cells were not significantly greater than
those seen in control A/J recipients (Fig. 6 A). In contrast,
clearly defined tetramer  populations were evident in the
recipients with high antichromatin titers.
To test for Tg T cell function, we conducted in vitro
proliferation assays using splenocytes from the  Tg recipi-
ents of both experiments. In all cases, purified T cells
proliferated poorly to the V  36-71 peptide. Fig. 6 B
illustrates results for the five  Tg recipients (second
experiment), which all had persistent antichromatin titers.
In these mice, an average of 2.3% of CD4  splenocytes
were tetramer . Nevertheless, their responses on a per cell
basis were less than one-tenth of that by tetramer  cells
from an immunized A/J recipient. Similar weak responses
were seen for tetramer  T cells from  Tg recipients of the
first experiment (unpublished data). Thus, chronic anti-
chromatin responses were accompanied by CA30 T cells in
 Tg recipients at late time points, but these cells demon-
strated severely diminished proliferative responses to anti-
gen in vitro.
Evidence of Inflammation and Kidney Involvement. To test
for antibody deposition in glomeruli, we stained frozen kid-
Figure 5. Induction of antichromatin IgG
in  Tg recipients of CA30 cells. (A, B, D,
and E) Chromatin-specific IgG antibody in
the sera of recipient mice. Counts detected
on BSA-coated plates were subtracted from
those detected on chromatin-coated plates at
each dilution point. Binding assays for dif-
ferent sera were conducted on the same day.
(C and F) Antinuclear staining of HEP-2
cells (sera diluted 1:100). 3H9 (V 4) is a
prototypic antinuclear mAb.
Figure 6. Persistent but refractive CA30 T
cells in some  Tg recipients. (A) Tetramer
staining of CD4  CD16 /CD32  spleno-
cytes of  Tg and A/J recipients killed 126 d
after CA30 cell transfer.  Tg mice nos. 1 and
2 and an A/J recipient mouse were immu-
nized 3 d before the stain (V  36-71 peptide,
30  g of i.p. CFA). These two mice pro-
duced a much weaker antichromatin Ab
response at day 76 than mice nos. 3 and 4,
which were left unimmunized. (B) Prolifera-
tive responses of splenocytes from long-term
 Tg recipients of CA30 cells (second experi-
ment). [3H]Thymidine incorporation, nor-
malized to frequencies of tetramer  cells, was
measured at day 5 in splenocyte cultures con-
taining 10 ng of V  36-71 peptide. A/J re-
cipients (closed squares) immunized on day
0. Five  Tg recipients (open circles) of 107
CA30 cells killed on day 130. These are the
same mice analyzed for antichromatin Ab
and kidney pathology in Figs. S4 and S5, and
in Table S4.T Cell Reactions to a   Variable Region Sequence 8
ney sections from  Tg recipients of CA30 cells with a panel
of antiisotype antibodies. Little or no staining was observed in
kidneys of mice killed at day 10 after transfer. However, by
day 28, some recipients of higher numbers of CA30 cells dis-
played infrequent segmental staining in a few glomeruli (3/10
mice). However, no evidence of disease was observed upon
H&E staining. At day 130, in contrast, kidneys of all five  Tg
recipients of 107 CA30 cells demonstrated global deposition of
antibody in virtually all glomeruli (Fig. 7 and Fig. S5, available
at http://www.jem.org/cgi/content/full/jem.20031234/DC1).
Moreover, H&E staining revealed enlarged glomeruli in four
out of five mice, with cellular infiltrates in two of these four
animals (unpublished data). In all five mice, antibodies of mul-
tiple classes, including IgM, IgG1, IgG2a, and IgG3 were de-
posited in glomeruli, with IgG1 and IgG2a predominating.
Of note, these are the same two classes that were found to
predominate in kidney deposits within spontaneously autoim-
mune (NZB   NZW)F1 mice (36). Because these were the
same five mice aforementioned that contained persistent anti-
chromatin Ab in sera, we were able to define their isotypes as
well. In the case of sera, the predominant serum antichroma-
tin IgG was IgG2a, followed by IgG3 and IgG2b (Table
S4, available at http://www.jem.org/cgi/content/full/jem.
20031234/DC1). The IgG2a and IgG3 subclasses are associ-
ated with the inflammatory cytokine, IFN- , which is known
to induce class switch recombination to  2a and  3 constant
region genes. IgG2a is also the predominant serum isotype of
antinuclear Ab in two widely studied murine models of spon-
taneous lupus: the (NZB   SWR)F1 mouse and the MRL
lpr/lpr mouse (37). Collectively, these data reveal manifesta-
tions of chronic lupuslike disease in recipients of T cells that
react to a BCR-derived peptide.
Discussion
To examine activation and self-tolerance in helper T
cells that are specific for BCR V regions, we generated a
line of    TCR Tg mice with CD4  T cells reactive to a
peptide derived from the somatically mutated   V region of
mAb 36-71. Central tolerance was examined by breeding
these CA30 Tg mice to mice expressing a 36-71  Tg, and
peripheral tolerance was assessed by transferring CA30 Tg
T cells into mice expressing the  Tg. Our results revealed
clear evidence of central tolerance by thymic deletion in
CA30 mice that either inherited the  Tg or that acquired
maternal antibody derived from it. However, results of pe-
ripheral tolerance studies were more complex. Transfer of
CA30 Tg T cells into  Tg recipients led to an initial wide-
spread activation of B cells; massive proliferation of CA30
T cells; and a graft-versus-host (GVH)–like disease mani-
fested by lymphadenopathy, splenomegaly, hypergamma-
globulinemia, and low levels of serum antichromatin Ab.
However, with time after transfer, hypergammaglobuline-
mia gave way to a stronger and more specific antichromatin
response with kidney pathology in most recipients, and this
was associated with a persistence of CA30 T cells. This an-
tichromatin response progressed through day 76 in seven
out of nine recipients, despite evidence of T cell tolerance
by day 28 as assessed by proliferative responses to the V 
36-71 peptide. To our knowledge, this is the first clear
example of chronic autoimmunity induced by a defined
CD4  T cell reactive with an Ig V region sequence. It
lends support to the hypothesis that BCR-derived peptides
may provide an avenue of T cell help to autoreactive B
cells in systemic autoimmune disease (17–23).
Evidence for central CD4  T cell tolerance to Ig se-
quences has been reported by several groups (38–42).
However, two Tg systems previously developed to address
this question yielded contrasting results. Bogen et al. (40)
found that T cells specific for a V region peptide from the  
light chain of MOPC-315 underwent thymic deletion in
mice that either expressed the cognate Ig or that were in-
jected with soluble antibody at a high concentration. These
results are consistent with others suggesting that wild-type
IgG2ab-specific T cells attain tolerance in the thymus (41).
In contrast, Granucci et al. (7) found that IgG2ab-specific T
cells from a TCR Tg mouse failed to undergo negative se-
lection in mice endogenously expressing IgG2ab. In agree-
Figure 7. Kidney pathology in
 Tg recipients of CA30 cells.
(A) Immunofluorescent detection
of IgG2a in kidneys of recipients
of CA30 cells. (bottom right)
Data are representative of all five
 Tg recipients at day 130. (top
right) Data show segmental stain-
ing seen at day 28 in 3 out of 10
mice that received CA30 cells.
Two of these mice received 107
CA30 cells, and the third received
106 cells. Magnification, 40. For
color images, see Fig. S5. (B) Iso-
type profile of IgG deposits and
H&E results for various kidney
sections. The two  Tg recipients
at day 28 (top) showed segmental
staining pattern. EG, enlarged
glomeruli; EGCI, enlarged glo-
meruli with cellular infiltration.Snyder et al. 9
ment with the MOPC-315 result, we observed a near
complete deletion of the Tg T cells. Although indirect evi-
dence has been published suggesting that maternally de-
rived Ig can induce central tolerance (3, 42–44), our results
provide the first direct evidence of thymocyte deletion re-
sulting from interactions with maternally derived Ig. Nev-
ertheless, although it is clear from our data that high levels
of serum Ig can induce central tolerance in Ig V region–
reactive CD4  T cells, it is still unclear whether this toler-
ance can be induced centrally by physiologically low levels
of IgM bearing a particular V region.
The consequences of a cognate T cell–B cell interaction
mediated by a BCR-derived V region peptide are largely
unknown. Two different outcomes might be predicted
from clues in the literature. Some evidence suggests that B
cells might be suppressed (3–5, 45). This outcome is pre-
dicted from studies using Ig allotype-specific T cells or
clones that induce allotype suppression. Results from other
models suggest instead that an Ig–peptide-directed interac-
tion between a CD4  T cell and a B cell will result in B
cell activation. Singh et al. (22) demonstrated that immuni-
zation of BALB/c mice with a V region peptide derived
from a lupus-associated Ab, resulted in transient autoanti-
body production. The striking implication of this result is
that chromatin-specific B cells received T cell help directed
to BCR V region–derived peptides that were self-pre-
sented by B cells in the context of class II MHC. The tem-
porary nature of autoantibody production observed by
Singh et al. is similar to what was seen in two of our  Tg
recipients of CA30 T cells. Our results are also reminiscent
of those from several models in which T cell help was di-
rected to peptides derived from natural or Tg-encoded
membrane antigens expressed by B cells (8–11). The early
hypergammaglobulinemia, splenomegaly, and lymphade-
nopathy seen in our transfer model are particularly reminis-
cent of CD4  T cell–induced GVH disease with lupuslike
manifestations (10, 11). Although it is clear that initial B
cell activation is multiclonal, more interesting is the time-
dependent specific increase in antichromatin IgG, which is
accompanied by a significant reduction of total serum IgG.
This indicates that chromatin-reactive B cells are selectively
stimulated with time after CA30 cell transfer. A common
feature of spontaneous murine lupus is a progressive, oligo-
clonal antichromatin response (17, 46, 47).
Although the outcomes of our transfer model and the
previously described models are similar in some respects,
our model is distinct in that recipient mice contained high
levels of serum Ig bearing the cognate T cell epitope. In
this sense, it is striking that CA30 Tg T cells were not im-
mediately rendered tolerant due to high levels of 36-71  
chain in recipient mice. There is considerable evidence that
IgG can be tolerogenic for CD4  T cells, and our recipient
mice contained milligram per milliliter quantities of serum
IgG  (48–53). However, studies from one group have pro-
vided evidence that IgM can be immunogenic (53–55).
Thus, it is possible that APCs presenting V  36-71 peptide
derived from IgM stimulated the transferred CA30 T cells
at early time points before tolerance could be induced by
APCs presenting V  36-71 peptide derived from IgG. The
subsequent rise in total IgG levels could explain an ob-
served delay in the acquisition of T cell tolerance; CA30
Tg T cells recovered 10 d after transfer proliferated strongly
in vitro in response to the V  36-71 peptide, whereas T
cells recovered 28 d after transfer were much less respon-
sive to antigenic stimulation.
Although all  Tg recipients of CA30 cells consistently
developed early manifestations of GVH-like disease, there
was considerable variation in the duration and level of the
specific antichromatin IgG response. Seven out of nine
mice had high serum Ab titers at day 76, and in six of these
mice, the titers were maintained or further increased to
varying levels at the final, 4-mo time point. The two recip-
ients with only low titers of antichromatin IgG at day 76
had no clearly detectable CA30 cells at the end point of the
experiment. In all others, defined populations were evident
upon tetramer staining. At face value, these observations
suggest that a persistent CA30 population is required for
long-term production of antichromatin Ab. Nevertheless,
the recovered CA30 cells responded only poorly to the V 
36-71 peptide in proliferation assays.
In a well-defined model of peripheral tolerance, transfer
of Tg CD4  T cells into a host ubiquitously expressing
cognate antigen led to a state of “adaptive tolerance” that
was manifested by poor proliferative and cytokine re-
sponses to antigen (56). An interesting feature of adaptive
tolerance is its apparent reversibility, which can occur if T
cells are removed from the antigenic environment that pro-
vides constant stimulation (57, 58). In our transfer model, it
is intriguing that an antichromatin IgG response persisted
in the face of antigen-refractive CA30 T cells. This appar-
ent discrepancy could be explained by the adaptive toler-
ance idea if chromatin-specific B cells are more effective
stimulators of T cells than are other APCs. CA30 T cells
that are refractive to the V  36-71 peptide presented by
professional APCs may be able to respond to the same pep-
tide that is self-presented by chromatin-specific B cells.
This might occur if the B cells present a higher concentra-
tion of the V  peptide due to BCR internalization after
chromatin engagement. Alternatively, chromatin-activated
B cells may provide enhanced or unique costimulatory sig-
nals for T helper cells. CpG motifs in chromatin apparently
enhance B cell activation by triggering Toll-like receptor 9
(59, 60). It is conceivable that this pathway might enhance
T cell costimulation as well. Further studies will be re-
quired to address this hypothesis.
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